The purpose of this study is to find out how well VDA-1102 ointment works compared to placebo ointment in treating a specific marker patch of actinic keratosis after twelve weeks of treatment. The marker patch is chosen as the one showing the most abnormal cell growth activity at the start of the study. During the trial, patients will apply the ointment to a specific area of their skin that contains several of these rough patches. The study will use a special imaging technique called LC-OCT, which is a type of scan that allows doctors to look at the deeper layers of skin without cutting into it, to measure changes in the skin patches.

Throughout the study, doctors will track several things including how many of the skin patches clear up completely or partially, changes in how the marker patch looks under the imaging scan, and the overall appearance of the treated skin area. Patients will apply the treatment for a period of twelve weeks, and doctors will monitor for any unwanted effects or reactions on the skin. The study may also include an optional skin sample taken from the marker patch to examine the tissue more closely under a microscope to better understand how the treatment is working at the cellular level.

The purpose of the study is to determine if using topical metformin alongside daylight photodynamic therapy can improve the treatment of actinic keratoses. Participants will receive the treatment for 12 weeks and will be monitored for an additional 36 weeks to observe the treatment’s effects and any potential side effects. The study will include a comparison with a placebo, which is a substance with no active medication, to better understand the treatment’s effectiveness.

Throughout the study, participants will apply the topical treatments to their skin, and the effects will be observed over time. The goal is to find out if this combination of treatments can effectively reduce the number of actinic keratoses and improve the condition of the skin. This research aims to provide new insights into managing skin lesions caused by sun damage.

Participants in the study will be randomly assigned to receive either the Solcera solution or a placebo. The treatment will be applied topically, meaning it will be put directly on the skin. The study will be conducted in multiple stages, and participants will be monitored throughout the treatment cycles to assess the clearance of actinic keratosis lesions. The study will evaluate the success of the treatment by checking if the skin lesions have completely cleared up after the treatment period.

The trial will also look at other factors, such as the overall condition of the skin over time, any side effects experienced, and the participants’ and investigators’ assessments of the treatment’s effectiveness and tolerability. The study aims to provide valuable information on the potential benefits of using Solcera for treating actinic keratosis, with the hope of offering a more effective treatment option for those affected by this skin condition.

The purpose of the study is to evaluate the effectiveness and safety of these two treatments in achieving complete clearance of actinic keratosis lesions. Participants will apply either Keramod® gel or Aldara® cream to the affected skin areas. The study will monitor the progress over a period of 24 weeks, with assessments at various points to check the reduction or clearance of the lesions.

Throughout the study, participants will be asked to complete questionnaires to assess their tolerance and satisfaction with the treatment. The study will also track how well participants adhere to the treatment schedule and any side effects they may experience. The ultimate goal is to determine which treatment is more effective in clearing actinic keratosis lesions while being well-tolerated by patients.

Participants in the study will receive treatment on two symmetrical areas of their skin. One area will be treated with both cryotherapy and tirbanibulin, while the other area will receive only cryotherapy. This will help researchers compare the effectiveness of the combination treatment against cryotherapy alone. The study will monitor changes in the number of actinic keratosis lesions over a period of three months. Researchers will also observe any skin reactions and assess the patients’ quality of life and satisfaction with the treatment.

The study aims to provide valuable information on whether the addition of tirbanibulin to cryotherapy offers better results for patients with actinic keratosis who have undergone organ transplants. By understanding the potential benefits and any side effects, this research could lead to improved treatment options for managing this skin condition in transplant recipients.

The purpose of the study is to determine if the combination treatment is as effective as using 5-Fluorouracil alone over a period of four weeks. Participants will apply the treatments to the affected areas of their skin. The study will last for a total of 12 months, with follow-up checks to see how well the treatments have worked. The main goal is to achieve a significant reduction in the number of Actinic Keratosis lesions, which are the rough patches on the skin.

Throughout the study, participants will be monitored to see how their skin responds to the treatments. The effectiveness of the treatments will be assessed by the reduction in the number of skin lesions, and any side effects will be recorded. The study will also look at the overall satisfaction of participants with their treatment and any changes in their quality of life. This research aims to provide valuable information on the best treatment options for managing Actinic Keratosis.

The purpose of the study is to assess how effective and safe this combined treatment is for patients with actinic keratosis on the scalp and forehead. Participants in the study will first receive cryotherapy, and then apply the tirbanibulin ointment. If the actinic keratosis persists after four months, the treatment may be repeated. The study will monitor the response to the treatment over a period of eight months, with a follow-up assessment at twelve months to see if the actinic keratosis has completely disappeared or if there has been a significant reduction in the number of lesions.

Throughout the study, researchers will also observe any local skin reactions, such as redness, peeling, or swelling, and assess any pain experienced by participants. The study aims to provide valuable information on the effectiveness of this treatment approach for actinic keratosis, potentially offering a new option for managing this common skin condition.

The purpose of the study is to determine the occurrence of a type of skin cancer called Squamous Cell Carcinoma and to evaluate the long-term safety of these treatments in adults with actinic keratosis on the face or scalp. Participants will be randomly assigned to use either tirbanibulin ointment or diclofenac gel. The study will last for three years, during which the safety and effectiveness of the treatments will be monitored.

Throughout the study, participants will apply the treatment to the affected area on their face or scalp. The tirbanibulin ointment is used for a short period of five days, while the diclofenac gel is used for a longer period of up to 90 days. The study aims to provide valuable information on the safety of these treatments and their ability to prevent the development of squamous cell carcinoma in patients with actinic keratosis.

The purpose of the study is to determine if Veregen 10% Ointment is more effective than the placebo in completely clearing the affected skin areas. Participants will apply the ointment to the affected areas for a period of 12 weeks, followed by a 4-week observation period. During this time, the study will monitor the skin for any changes, aiming for complete disappearance of the Actinic Keratosis patches.

Throughout the study, participants will have regular check-ups to assess the condition of their skin and to ensure their safety. The study will also continue to monitor participants for a year after the treatment to observe any long-term effects or recurrence of the skin condition. This trial aims to provide valuable information on the potential benefits of using Veregen 10% Ointment for treating Actinic Keratosis on the scalp and face.

The purpose of the study is to assess how effective Tirbanibulin is in treating Actinic Keratosis compared to a placebo, which looks like the treatment but does not contain the active ingredient. Participants in the study will apply the ointment to a specific area of their skin that is larger than 25 cm² and up to 100 cm². The study will last for several weeks, with the main evaluation taking place at Day 57, which is about eight weeks after starting the treatment. Some participants may receive a second course of treatment, and their progress will be checked again by Day 113.

Throughout the study, the number of skin lesions will be counted and compared to the initial count to determine the treatment’s effectiveness. The study aims to see if there is a significant reduction in the number of lesions and if the skin clears up completely in some cases. This research is important for finding better ways to manage and treat Actinic Keratosis, providing valuable information on the potential benefits of Tirbanibulin ointment for patients with this condition.